Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

Moderna

Moderna

MRNA

0.00

BERLIN, June 17 (Reuters) - U.S. pharmaceutical company Moderna MRNA.O is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stephane Bancel told the German business daily Handelsblatt on Wednesday.

"If we were to find the right partnership with the German government, these facilities would be an interesting option -compared with building a new one," Bancel said.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.